DE602005022475D1 - Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen - Google Patents

Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen

Info

Publication number
DE602005022475D1
DE602005022475D1 DE602005022475T DE602005022475T DE602005022475D1 DE 602005022475 D1 DE602005022475 D1 DE 602005022475D1 DE 602005022475 T DE602005022475 T DE 602005022475T DE 602005022475 T DE602005022475 T DE 602005022475T DE 602005022475 D1 DE602005022475 D1 DE 602005022475D1
Authority
DE
Germany
Prior art keywords
antibodies
binding partners
infliction
applying
antagonizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005022475T
Other languages
English (en)
Inventor
Wenfeng Xu
Wayne R Kindsvogel
Yasmin A Chandrasekher
Stacey R Dillon
Joyce M Lehner
Anthony W Siadak
Pallavur V Sivakumar
Margaret D Moore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of DE602005022475D1 publication Critical patent/DE602005022475D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
DE602005022475T 2004-10-22 2005-10-21 Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen Active DE602005022475D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62155304P 2004-10-22 2004-10-22
PCT/US2005/037821 WO2006047249A1 (en) 2004-10-22 2005-10-21 Anti-il-22ra antibodies and binding partners and methods of using in inflammation

Publications (1)

Publication Number Publication Date
DE602005022475D1 true DE602005022475D1 (de) 2010-09-02

Family

ID=35871017

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005022475T Active DE602005022475D1 (de) 2004-10-22 2005-10-21 Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen

Country Status (22)

Country Link
US (5) US7537761B2 (de)
EP (1) EP1812476B1 (de)
JP (1) JP4898691B2 (de)
KR (1) KR101238684B1 (de)
CN (1) CN101198625A (de)
AT (1) ATE474856T1 (de)
AU (1) AU2005299809B2 (de)
BR (1) BRPI0516975A (de)
CA (1) CA2584157C (de)
CY (1) CY1110843T1 (de)
DE (1) DE602005022475D1 (de)
DK (1) DK1812476T3 (de)
EA (1) EA015706B1 (de)
ES (1) ES2347672T3 (de)
HK (1) HK1110333A1 (de)
IL (2) IL182503A (de)
MX (1) MX2007004770A (de)
NO (1) NO20072602L (de)
PT (1) PT1812476E (de)
UA (1) UA96122C2 (de)
WO (1) WO2006047249A1 (de)
ZA (1) ZA200704125B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
CA2418950A1 (en) * 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
WO2004085475A2 (en) * 2003-03-24 2004-10-07 Zymogenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
ATE447587T1 (de) * 2003-11-21 2009-11-15 Zymogenetics Inc Anti-il-20-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
CN101198625A (zh) * 2004-10-22 2008-06-11 津莫吉尼蒂克斯公司 抗il-22ra抗体和结合伴侣及其在炎症中的使用方法
CA2631961A1 (en) * 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling relating to antibodies that bind to il-22
WO2011047153A1 (en) * 2009-10-15 2011-04-21 President And Fellows Of Harvard College Methods for modulating autoimmunity
MX2012005791A (es) * 2009-11-19 2012-07-03 Merck Serono Sa Anticuerpos humanizados contra el receptor alfa de la interleucina 22 humana.
RS61082B1 (sr) 2010-02-26 2020-12-31 Novo Nordisk As Stabilno antitelo koje sadrži kompozicije
WO2011147921A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
US20140044731A1 (en) 2011-01-04 2014-02-13 Robert Nussenblatt Methods of treating age-related macular degeneration
TR201807202T4 (tr) 2011-03-16 2018-06-21 Argenx Bvba CD70 antikorları.
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
EP3442562B1 (de) * 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd Ein il-22-dimer zur verwendung in der behandlung der nekrotisierenden enterokolitis
EP3464357A1 (de) 2016-05-24 2019-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur behandlung von bakteriellen lungeninfektionen
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
JP2020513574A (ja) * 2016-11-24 2020-05-14 ヒュベット バイオ, インコーポレイテッドHuvet Bio, Inc. 疾患の診断用組成物
US11834472B2 (en) 2018-06-05 2023-12-05 Bioatla, Inc. Anti-IL-22 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN110078832B (zh) * 2019-04-18 2021-12-14 江南大学 一类基于ZZ domain的二抗及其制备方法和应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
EP0154316B1 (de) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemisch modifizierte Lymphokine und Verfahren zu ihrer Herstellung
NZ212437A (en) 1985-06-17 1992-06-25 Mark Philip Best Site-directed antibody conjugates, and their preparation
WO1989004838A1 (en) * 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5436155A (en) * 1991-12-31 1995-07-25 Arch Development Corporation Isolated DNA encoding a somatostatin receptor
US5789192A (en) * 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
DK0912734T3 (da) 1996-07-12 2011-02-07 Genentech Inc Kimæriske heteromultimer-adhæsiner
US5843697A (en) 1996-07-17 1998-12-01 University Of Medicine And Dentistry Of New Jersey Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein
US5985614A (en) * 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
WO2000012708A2 (en) 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
EP1012260A4 (de) 1997-07-16 2001-05-09 Human Genome Sciences Inc Interleukin-20
US6486301B1 (en) 1997-07-16 2002-11-26 Human Genome Sciences, Inc. Interleukin-20
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
JP2001512668A (ja) 1997-08-06 2001-08-28 ザイモジェネティクス，インコーポレイティド リポカリン相同体
US6551799B2 (en) 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
NZ504751A (en) 1997-11-26 2001-10-26 Zymogenetics Inc Polynucleotide encoding the mouse Zcyto10 polypeptide and related antibodies and anti-idiotypic antibodies
US6576743B1 (en) * 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
CA2318482C (en) 1998-01-23 2010-04-13 Immunex Corporation Il-18 receptors
WO1999046379A2 (en) 1998-03-09 1999-09-16 Schering Corporation Human receptor proteins; related reagents and methods
EP1490386B1 (de) 1998-03-10 2008-08-13 Genentech, Inc. Neuartiges polypeptid und dessen kodierende nukleinsäuren
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
AU5203199A (en) 1998-05-26 1999-12-13 Procter & Gamble Company, The Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
WO2000006605A2 (en) 1998-07-28 2000-02-10 Micromet Ag Heterominibodies
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
AU760224B2 (en) 1998-10-26 2003-05-08 Wyeth Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
AU2222700A (en) 1998-12-31 2000-07-31 Millennium Pharmaceuticals, Inc. Class ii cytokine receptor-like proteins and nucleic acids encoding them
BR0010097A (pt) 1999-04-28 2002-02-13 Genetics Inst Polinucleotìdeo isolado; célula hospedeira; processo para a produção de uma proteìna codificada pelo polinucleotìdeo; proteìna; composição; e; anticorpo
EP1179066A2 (de) 1999-05-19 2002-02-13 Incyte Genomics, Inc. Extrazelluläre signalmoleküle
AU5047600A (en) 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
ATE449109T1 (de) 1999-06-15 2009-12-15 Genentech Inc Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung
AU2883700A (en) 1999-06-23 2001-01-09 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE60045931D1 (de) 1999-07-07 2011-06-16 Zymogenetics Inc Menschliches Rezeptor für Zytokine
AU7573000A (en) 1999-09-01 2001-03-26 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1230368A2 (de) 1999-11-18 2002-08-14 Schering Corporation Rezeptorproteine aus säugetieren; verwandte reagenzien und verfahren
JP2003534773A (ja) * 1999-12-03 2003-11-25 ザイモジェネティクス，インコーポレイティド ヒトサイトカイン受容体
US6610286B2 (en) * 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
PT1616575E (pt) 1999-12-23 2012-08-07 Zymogenetics Inc Método para tratar inflamação
WO2001046422A1 (en) 1999-12-23 2001-06-28 Zymogenetics, Inc. Novel cytokine zcyto18
WO2001046232A2 (en) 1999-12-23 2001-06-28 Zymogenetics, Inc. Soluble interleukin-20 receptor
NZ523122A (en) 2000-06-22 2004-06-25 Smithkline Beecham Corp Polypeptides and polynucleotides and methods of identifying agonists and antagonists in relation to treatment of diseases
JP2002015498A (ja) 2000-06-29 2002-01-18 Fujitsu Ltd センス電流の設定方法
CA2418950A1 (en) 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
JP2004509617A (ja) 2000-09-08 2004-04-02 シェーリング　コーポレイション 哺乳動物遺伝子；関連試薬および方法
DE60121808T2 (de) * 2000-09-15 2007-03-29 Zymogenetics, Inc., Seattle Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
EP1191035A3 (de) 2000-09-25 2002-04-17 Schering Aktiengesellschaft Drei Mitglieder der Zytokinrezeptorfamilie Klasse II
US20030022827A1 (en) * 2000-09-25 2003-01-30 Bertram Weiss Three new members of the cytokine receptor family class 2
WO2002066647A2 (en) 2001-01-12 2002-08-29 Genetics Institute, Llc. Type 2 ctokine receptor and nucleic acids encoding same
EP1390060A2 (de) 2001-01-26 2004-02-25 Eli Lilly And Company Verwendung von lp82 zur behandlung von störungen des körpergewichtes
AU2002252097A2 (en) 2001-02-23 2002-09-12 Genetics Institute, Llc Composition and method for treating inflammatory disorders
MXPA03007653A (es) 2001-02-28 2003-12-04 Lilly Co Eli Uso de lp82 para tratar trastornos hematopoyeticos.
JP2004532624A (ja) * 2001-03-02 2004-10-28 ザイモジェネティクス，インコーポレイティド マウスサイトカイン受容体
US20040086908A1 (en) 2002-03-07 2004-05-06 Chandrasekher Yasmin A. Soluble heterodimeric cytokine receptor
DE60232511D1 (de) 2001-03-09 2009-07-16 Zymogenetics Inc Löslicher heterodimerer cytokinrezeptor
AU2002252460A1 (en) 2001-03-27 2002-10-08 Zymogenetics, Inc. Human cytokine receptor
PT2163256E (pt) 2001-05-11 2015-11-20 Ludwig Inst For Cancer Res Ltd Proteínas de ligação específica e suas utilizações
US20040204351A1 (en) 2001-10-22 2004-10-14 Rowlinson Scott William Soluble proteins that inhibit cytokine signal transduction pathways
DE10154579A1 (de) 2001-11-07 2003-05-28 Medigene Ag Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
JP4532902B2 (ja) 2001-12-17 2010-08-25 ザイモジェネティクス，インコーポレイティド 子宮頸部癌の治療方法
US20040236075A1 (en) 2002-07-24 2004-11-25 Laure Dumoutier Novel glass II cytokine receptors, and uses thereof
WO2004085475A2 (en) * 2003-03-24 2004-10-07 Zymogenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
ATE447587T1 (de) * 2003-11-21 2009-11-15 Zymogenetics Inc Anti-il-20-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
CN101198625A (zh) 2004-10-22 2008-06-11 津莫吉尼蒂克斯公司 抗il-22ra抗体和结合伴侣及其在炎症中的使用方法
MX2012005791A (es) * 2009-11-19 2012-07-03 Merck Serono Sa Anticuerpos humanizados contra el receptor alfa de la interleucina 22 humana.

Also Published As

Publication number Publication date
CA2584157A1 (en) 2006-05-04
DK1812476T3 (da) 2010-10-25
CY1110843T1 (el) 2015-06-10
US8536309B2 (en) 2013-09-17
US20100210825A1 (en) 2010-08-19
AU2005299809A2 (en) 2006-05-04
ATE474856T1 (de) 2010-08-15
US8124088B2 (en) 2012-02-28
KR101238684B1 (ko) 2013-03-04
US7537761B2 (en) 2009-05-26
ES2347672T3 (es) 2010-11-03
AU2005299809A1 (en) 2006-05-04
PT1812476E (pt) 2010-11-08
WO2006047249A1 (en) 2006-05-04
AU2005299809B2 (en) 2010-12-02
US20130315919A1 (en) 2013-11-28
EP1812476B1 (de) 2010-07-21
US20120156210A1 (en) 2012-06-21
US20060141582A1 (en) 2006-06-29
ZA200704125B (en) 2008-09-25
EA015706B1 (ru) 2011-10-31
UA96122C2 (ru) 2011-10-10
HK1110333A1 (en) 2008-07-11
IL182503A0 (en) 2007-09-20
CA2584157C (en) 2014-10-14
JP4898691B2 (ja) 2012-03-21
IL207146A0 (en) 2010-12-30
CN101198625A (zh) 2008-06-11
JP2008517922A (ja) 2008-05-29
IL207146A (en) 2012-06-28
KR20070084486A (ko) 2007-08-24
US20090220519A1 (en) 2009-09-03
MX2007004770A (es) 2007-11-22
IL182503A (en) 2012-01-31
NO20072602L (no) 2007-07-23
EA200700916A1 (ru) 2007-10-26
EP1812476A1 (de) 2007-08-01
US7871616B2 (en) 2011-01-18
BRPI0516975A (pt) 2008-09-30

Similar Documents

Publication Publication Date Title
DE602005022475D1 (de) Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
ATE475673T1 (de) Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
MXPA06014465A (es) Zcytor14 soluble, anticuerpos anti-zcytor14 y moleculas de union y metodos de uso en inflamacion.
WO2006086396A3 (en) Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
WO2005052001A3 (en) Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
DE602007006429D1 (de) Lösliches il-17rcx4 und verfahren zu dessen anwendung bei entzündungen
TW200745163A (en) Peptides that block the binding of IgG to FcRn
ME00185B (me) Specifični agensi koji vezuju humani angiopoetin-2
ATE485517T1 (de) Verfahren zur identifizierung von polypeptid- targets
WO2008049070A3 (en) Il-17c antagonists and methods of using the same
WO2005099755A3 (en) Methods of treating autoimmune and inflammatory diseases
EA200700823A1 (ru) Растворимый zcytor21, анти-zcytor21 антитела и связывающие партнёры и способы применения при воспалении
ATE397085T1 (de) Verfahren zur reproduzierung von pleuromutilinen
DE602004015468D1 (de) Verfahren zur aufreinigung eines nichtimmunoglobulinproteins, das eine immunoglobulinähnliche (ig-like) domäne enthält
ATE437650T1 (de) Tyrosinasemutante und verfahren zur verwendung davon
DE60232195D1 (de) Verfahren und neue primer zur untersuchung von schizophrenie